Bristol-Myers sues DRL for patent infringement in US

US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
Real-time Stock quotes, portfolio, LIVE TV and more.
GeStepAhead SME Special
moneycontrol.com

Home » News » World News

Dec 28, 2012, 09.02 AM | Source: PTI

Bristol-Myers sues DRL for patent infringement in US

US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra.

Like this story, share it with millions of investors on M3

Bristol-Myers sues DRL for patent infringement in US

US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra.

Post Your Comments

Share Cancel

US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra. Bristol-Myers in its petition filed in the United States District Court of New Jersey alleged that the Indian drug maker has infringed the patents of its drug on three counts.

Also read: Plan panel sets $100 bn target for pharma sector by 2020
    
According to the petition, by a letter dated November 13, 2012, DRL notified Bristol-Myers that the Indian drug major had submitted Abbreviated New Drug Application (ANDA) concerning its proposed drug product of Ixabepilone for injection, as required by the FDA rules.
   
DRL's letter further notified that Ixabepilone injection patents are invalid and or will not be infringed by the commercial manufacture, use, offer for sale, or sale of DRL's ANDA product, the petition said.
   
Ixempra, used in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane (chemotherapy agents) has nearly USD 120 million sales, according to market reports. When contacted, a DRL spokesperson said, "Our intellectual properties (IP) teams keep working on patent infringement cases and engage in related legal activities."
    
"A permanent injunction enjoining DRL, its affiliates and subsidiaries, and all persons and entities acting in concert with DRL from commercially manufacturing, using, offering for sale, or selling DRL's ANDA product within the US .. until the expiration of the '384 ( 330, 393 ) patent..." Bristol Myers urged the court.
    
Besides, the US drug maker requested the court to award damages or other relief if DRL engages in commercial manufacture or sale of DRL's Abbreviated New Drug Application product, or any product that infringes the patents of the drug.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Bristol-Myers sues DRL for patent infringement in US

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login